ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO423

Family Screening Among CKD Patients with Fabry Disease: A Very Important and Underrated Task

Session Information

Category: Genetic Diseases of the Kidneys

  • 1002 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Sodré, Luciana Senra de Souza, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil
  • Huaira, Rosalia Maria nunes henriques, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil
  • Colugnati, Fernando Antonio basile, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil
  • Coutinho, Marcelo Paula, Datagenno, Campos dos Goytacazes, Brazil
  • Fernandes, Natalia Maria da silva, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil
Background

Introduction: Fabry disease is a chronic, progressive and multi-systemic hereditary condition, related to a Xq22 mutation in X chromosome, which results in deficiency of acid alpha-galactosidase, hence reduced capacity of globotriaosylceramide (Gb3) degradation. Gb3 accumulates in lysosomes throughout virtually every organ, thus carrying considerable morbidity and mortality.

Objective: Evaluate the prevalence of Fabry disease, as well as its signs and symptoms, among relatives of chronic kidney disease (CKD) patients diagnosed with Fabry disease during a previously conducted study, entitled “Clinical and epidemiological analysis of Fabry disease in dialysis centers in Brazil – the Brazil Fabry Kidney project”.

Methods

Transversal study, interviewing the relatives of patients and performed blood tests for both Gb3 dosage and genetic testing.

Results

Among 1214 interviewed relatives, 115 (9.47%) were given the diagnosis of Fabry disease, with a predominance of women (66.10%). The most prevalent comorbidities were rheumatologic conditions and systemic hypertension (1.7% each), followed by heart, neurological and cerebrovascular disease, and depression, in 0.9% of individuals. Intolerance to physical exercise and tiredness were observed in 1.7%, followed by periodic fever, intolerance to heat or cold, diffuse pain, burn sensation or numbness in hands and feet, reduced or absent sweating, as well as abdominal pain after meals, in 0.9%.

Conclusion

Family screening of Fabry disease is highly indicated, since we found a prevalence of 9.47% of relatives of CKD patients with this condition, remarkably with a 66.1% predominance of women, which contrasts with previous reports.